A new publication referencing GHK-Cu appeared on October 2, 2026. The paper, titled "Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence," was published in the journal Life (Basel, Switzerland).
The publication addresses classification of peptides used in aesthetic dermatology, fibroblast-centered mechanisms, delivery technologies, and clinical evidence related to this category of compounds. GHK-Cu is named within this broader subject area covered by the article.
This entry reflects the release of the publication itself, not a summary of its findings or conclusions. No specific data, results, or outcomes from the paper are described here. Readers interested in the full scope of the discussion, including the mechanisms and evidence presented, are encouraged to consult the original article directly through the provided source link.
GHK-Cu is currently classified as an approved compound. This brief is intended only to note the existence and bibliographic details of this new publication as of its listed date. For additional background on GHK-Cu, including its general profile and context, readers can refer to the compound overview.